Uenami Takeshi, Ishijima Mikako, Kanazu Masaki, Kurebe Hiroyuki, Edahiro Ryuya, Nishida Kohei, Akazawa Yuki, Yano Yukihiro, Yamaguchi Toshihiko, Mori Masahide
Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Osaka, Japan.
Ann Transl Med. 2018 Nov;6(22):444. doi: 10.21037/atm.2018.10.24.
Recently, the immune checkpoint inhibitor (ICI) pembrolizumab was demonstrated to be superior to platinum doublet chemotherapy in the first-line setting in patients with tumor programmed death-ligand 1 (PD-L1) expression of at least 50%. However, because patients with epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements were not included in that study, the efficacy of pembrolizumab in lung cancers carrying EGFR mutations could not be determined. Here we describe two cases of response to pembrolizumab in EGFR mutated lung adenocarcinoma patients with PD-L1 overexpression. These cases indicate that ICI is an effective treatment for EGFR mutated lung adenocarcinoma patients with PD-L1 overexpression.
最近，免疫检查点抑制剂（ICI）帕博利珠单抗在一线治疗中被证明优于铂类双药化疗，适用于肿瘤程序性死亡配体1（PD-L1）表达至少为50%的患者。然而，由于该研究未纳入表皮生长因子受体（EGFR）突变或间变性淋巴瘤激酶（ALK）重排的患者，因此无法确定帕博利珠单抗在携带EGFR突变的肺癌中的疗效。在此，我们描述了2例PD-L1过表达的EGFR突变肺腺癌患者对帕博利珠单抗产生反应的病例。这些病例表明，ICI是治疗PD-L1过表达的EGFR突变肺腺癌患者的有效疗法。
